The safety and effectiveness of yttrium-90 radioembolization for hepatocellular carcinoma with portal vein tumor thrombosis

VernacularTitle:钇-90微球放射栓塞治疗肝细胞性肝癌伴门静脉癌栓的安全性与疗效评价
Author: Zhongzhi JIA ¹ ; Chunfu ZHU ; Houyun XU ; Xihu QIN
Author Information

1. 常州市第二人民医院介入血管科
Keywords: Yttriumisotopes; Carcinoma,hepatocellular; Portal vein
From: Chinese Journal of General Surgery 2019;34(5):439-443
CountryChina
Language:Chinese
Abstract: Objective To assess the safety and effectiveness of yttrium-90 (90Y) radioembolization for patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombosis (PVTT).Methods The PubMed was searched for all clinical reports from 1991 to 2017.Results A total of 17 clinical studies including 662 patients were qualified for the analysis.The median time to progression was 5.8 months,and median disease control rate was 68.4％.The median survival was 10 months in all patients,including the median OS of 13.8,6.5 months of Child-Pugh class A and B patients,respectively,the median OS were 13.4,5.4 months respectively in branch and main PVTT patients,and the median OS were 3.7,9.5 months of patients who received resin and glass based microspheres,respectively.The median radioembolization induced liver disease was 36.3％.The median abdominal pain,nausea/vomiting,fatigue,and fever were 18.8％,17.6％,11.1％,and 1.4％.Conclusion 90y radioembolization is an effective treatment for HCC and PVTT,which is an alternative treatment choice for HCC and PVTT.